136 related articles for article (PubMed ID: 37668187)
1. Laboratory-guided repeat dosing of idarucizumab for dabigatran reversal.
Jones H; De Simone N; Webb C
Clin Toxicol (Phila); 2023 Aug; 61(8):622-623. PubMed ID: 37668187
[No Abstract] [Full Text] [Related]
2. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
3. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
6. Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre.
Wheeler M; Borrie A; Dookia R; Carter J
Intern Med J; 2019 Oct; 49(10):1316-1320. PubMed ID: 31602769
[TBL] [Abstract][Full Text] [Related]
7. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
Pollack CV
Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab: The Antidote for Reversal of Dabigatran.
Eikelboom JW; Quinlan DJ; van Ryn J; Weitz JI
Circulation; 2015 Dec; 132(25):2412-22. PubMed ID: 26700008
[No Abstract] [Full Text] [Related]
10. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
11. Idarucizumab for dabigatran overdose in a child.
Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
[TBL] [Abstract][Full Text] [Related]
13. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
Giannandrea D; Mengoni A; Carluccio E; Ambrosio G
Vasc Health Risk Manag; 2019; 15():139-142. PubMed ID: 31213821
[TBL] [Abstract][Full Text] [Related]
14. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
[TBL] [Abstract][Full Text] [Related]
15. Idarucizumab for Dabigatran Reversal Guideline.
Reardon DP; Owusu K
Crit Pathw Cardiol; 2016 Jun; 15(2):33-5. PubMed ID: 27183250
[No Abstract] [Full Text] [Related]
16. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
17. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
[TBL] [Abstract][Full Text] [Related]
18. [Severe dabigatran intoxication complicated by insufficient reversal by idarucizumab].
Hellfritzsch M; Hvas AM
Ugeskr Laeger; 2020 Apr; 182(15):. PubMed ID: 32286218
[TBL] [Abstract][Full Text] [Related]
19. Assessment of patients post reversal with idarucizumab.
Raco V; Ahuja T; Green D
J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab: What Should We Know?
Cortese F; Calculli G; Gesualdo M; Cecere A; Zito A; De Vito F; Carbonara R; Carbonara S; Cortese AM; Ciccone MM
Curr Drug Targets; 2018; 19(1):81-88. PubMed ID: 28950812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
